Aspirin only benefits Diabetics with history of Heart Disease or Stroke

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
BMJ published, 16 October 2008

What is already known on this topic
Aspirin is effective in the secondary prevention of cardiovascular events in patients with symptomatic peripheral arterial disease and with or without diabetes.
Aspirin is responsible for significant gastrointestinal morbidity.
No large intervention trial has shown any reduction of events with antioxidant intervention.

What this study adds
Aspirin was not effective in the primary prevention of cardiovascular events in patients with asymptomatic peripheral arterial disease and diabetes.
Antioxidants showed no benefit on cardiovascular events in this population.